El interés en corto de KraneShares MSCI All China Health Care Index ETF da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de KraneShares MSCI All China Health Care Index ETF. Los datos de interés en corto se actualizan cada dos semanas.

KraneShares MSCI All China Health Care Index ETF (ARCA:KURE), Informe de interés en corto

Healthcare

Technology

Other

Consumer Cyclical

Real Estate

The fund will invest at least 80% of its total assets in components of the underlying index, depositary receipts, including American depositary receipts, representing such components and securities underlying depositary receipts in the underlying index. The underlying index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the healthcare sector.

Jiangsu Hengrui Medicine Co Ltd

Beigene Ltd Ord Hkd 0.0001

Legend Biotech Corp

Akeso,inc

KraneShares MSCI All China Health Care Index ETF

Eli Lilly and Co.

Equities

Government

News

Markets

ABBV

AMGN

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

REGN

Trump quiere que las farmacéuticas vuelvan a EE. UU. ¿Cómo afectarán sus aranceles a las acciones del sector?

Trump presiona a farmacéuticas con aranceles para forzar regreso a EE. UU.

KURE TECHNOLOGIES INC by Kure Technologies, Inc.

Kure Technologies Inc

Kureha Corp

WIIM

AngloGold Ashanti shares are trading higher after the company announced the sale of its Brazilian mine for $76 million.

Contracts

WETO

Webus Signs Up To $300M XRP Treasury Management Agreement With Samara Alpha

APLD

CRWV

Applied Digital Enters 15-Year Lease Agreements With CoreWeave, Expects $7B Revenue Over Term

-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors --
-- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who had progressed after two prior lines of therapy, including a prior MEK inhibitor + BRAF inhibitor combination therapy, achieves over 5 months of stable disease with tumor volume reduction of -14.9% and remains on treatment&nbsp;--
-- PAS-004 pharmacokinetics profile potentially supports a prolonged target engagement at well-tolerated doses --
MIAMI, June 02, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Gyyu_Ateu17Frjrozk-mYaa2RiHL4zBXuJRXUxMU4607pJ9BlSSTwEXVxCDE5VU-N_m2i5ryv2LROu8eB4_Q7j6ToHVi7B-hp9xK_l3IUTg=">Pasithea Therapeutics Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced updated interim results from its ongoing dose escalation Phase 1 study evaluating PAS-004 in advanced cancer patients in a poster presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
The Phase 1 clinical trial is a multi-center, open-label, dose escalation, modified 3+3 study design to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation, or patients who have failed BRAF/MEK inhibition (NCT06299839).
As of the cut-off date of April 2, 2025, a total of 21 patients had been enrolled and received at least one dose of PAS-004 in six cohorts (Capsules: 2mg, 4mg, 8mg, 15mg, 22mg / Tablets: 4mg). The most common cancer diagnosis was pancreatic cancer (28.6%), colorectal cancer (28.6%), and melanoma (23.8%).
All treatment-related adverse events (AEs) have been either grade 1 or grade 2. No known MEK inhibitor class-related AEs such as ocular toxicities, cardiotoxicities, and skin toxicities were observed during the DLT observation period. No DLTs were reported, and dose escalation is ongoing.
Preliminary PAS-004 PK analysis suggests linear PK with an estimated half-life in excess of 60 hours. The Cmax (peak) to Cmin (trough) ratio was below 2 at steady state in all dose levels and has achieved potentially sufficient exposures for target engagement. This is supported by previously reported preliminary pERK inhibition observed in cohort 3 (8mg capsule), with pERK inhibition of up to 91%.

Biotech

General

KTTA

Pasithea Announces Its PAS-004 Shows Early Activity And Durable Disease Stability In Heavily Pretreated Solid Tumors, Including BRAF-Mutated Melanoma, With Favorable Safety And Pharmacokinetics In Ongoing Phase 1 Dose Escalation Trial

AstraZeneca and Daiichi Sankyo's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years
First trial in more than a decade to demonstrate an improvement in outcomes in the 1st-line setting for a broad population of patients with HER2-positive metastatic breast cancer
Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU&#xAE; (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzumab (THP) as a 1st-line treatment for patients with HER2-positive metastatic breast cancer.
Results will be presented today during a special late-breaking oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL (abstract #LBA1008).
In a prespecified interim analysis, ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% versus THP (based on a hazard ratio [HR] of 0.56; 95% confidence interval [CI] 0.44-0.71; p&lt;0.00001). Median PFS was 40.7 months with ENHERTUplus pertuzumab compared to 26.9 months for THP, as assessed by blinded independent central review (BICR). The PFS benefit for ENHERTU plus pertuzumab versus THP was consistent across subgroups, including for the prespecified stratification factors of de novo or recurrent disease, hormone receptor status and PIK3CA mutation status.

AstraZeneca And Daiichi Sankyo's ENHERTU Plus Pertuzumab Shows Median Progression-Free Survival Greater Than Three Years

Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda&#xAE; (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in Trial in Progress Poster at ASCO
Phase 3 trial of IFx-Hu2.0 to be conducted under Accelerated Approval Pathway and Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA)

HURA

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster At 2025 ASCO Annual Meeting

Jefferies analyst Andrew Andersen initiates coverage on Aspen Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with a Buy rating and announces Price Target of $42.

Price Target

Initiation

Analyst Ratings

Jefferies Initiates Coverage On Aspen Insurance Hldgs with Buy Rating, Announces Price Target of $42

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) can go higher. &#8220;Because it's Brad Jacobs [Chairperson of QXO]. He will not let it stay <a href="https://www.benzinga.com/quote/QXO/earnings">down here,&#8221; he added.</a>
As per recent news, QXO filed for the resale of 67.5 million shares of common stock by the selling stockholders on May 29.
Gentex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) is a very good company, Cramer said. &#8220;I cannot believe how low it's gotten,&#8221; he added.
Lending support to his choice, the company reported quarterly earnings per share of 42 cents on April 25, in line with the analyst consensus estimate. Revenues of $576.8 million (down 2% year over year) outpaced the street view of $571.97 million.
Cramer said although Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is an &#8220;absolutely terrific&#8221; company, he prefers ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) more.
On the earnings front, Energy Transfer reported quarterly earnings of 36 cents per share on May 6, which missed the analyst consensus estimate of 37 cents per share. The company reported quarterly sales of $21.02 billion, which also missed the analyst consensus estimate of $21.54 billion.
When asked about The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), he said, &#8220;I should have told people to pull the trigger after that one unfortunate quarter that Jeff Green had.&#8221;
Trade Desk, on May 8, reported quarterly earnings of 33 cents per share, which beat the analyst consensus estimate of 25 cents. Quarterly revenue clocked in at $616.02 million, which beat the consensus estimate of $584.27 million and represents a 25.4% increase over revenue of $491.25 million from the same period last year.
Price Action:
<ul class="wp-block-list">
<li>QXO shares fell 0.6% to settle at $17.00 on Friday.</li>
<li>Trade Desk shares gained 0.5% to close at $75.22.</li>
<li>Gentex shares fell 1% to close at $21.57 during the session.</li>
<li>Energy Transfer shares fell 1.1% to settle at $17.48 on Friday.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image created using photos from Shutterstock.

Large Cap

Long Ideas

Media

Trading Ideas

GNTX

Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

JPMorgan CEO Dimon, Speaking On Fox Business Said JPM Will Be At The Forefront Of Crypto

Esperion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited (together, Hetero USA). This agreement resolves the patent litigation brought by Esperion against Hetero USA in response to Hetero USA' s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Hetero USA has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.
The pending patent litigation against the remaining defendants (Accord Healthcare Inc; Alkem Laboratories Ltd.; Aurobindo Pharma Limited (along with an affiliate); Dr. Reddy's Laboratories Inc. (along with an affiliate); MSN Pharmaceuticals Inc. (along with an affiliate); Renata Limited; and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of NEXLETOL and/or NEXLIZET, as applicable, to be marketed in the U.S. prior to April 19, 2040.

Legal

ESPR

Esperion Reaches Settlement With Hetero USA To Delay Generic NEXLETOL Launch Until 2040, While Patent Litigation Against Additional Generic Challengers Remains Ongoing

ASND

Ascendis Pharma Announced FDA Acceptance For Priority Review Of New Drug Application For TransCon CNP For Children With Achondroplasia And Set Prescription Drug User Fee Act Goal Date Of Nov. 30, 2025 To Complete Review.

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>).
The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">early-stage immunology pipeline</a>.
Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM &amp; ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs.
The acquisition will also include elenestinib, a next-generation medicine for SM, and BLU-808, a highly selective and potent oral wild-type KIT inhibitor with the potential for immunology diseases.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/41987123/blood-cancer-focused-blueprint-medicines-could-be-attractive-target-for-partnerships-analyst-initiates-with-around-30-upside" rel="noreferrer noopener">Blood Cancer-Focused Blueprint Medicines Could Be &#8216;Attractive Target For Partnerships&#8217;: Analyst</a>
Sanofi will pay&nbsp;$129.00&nbsp;per share in cash, representing an equity value of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45714358/sanofi-to-acquire-blueprint-medicines-expanding-portfolio-in-rare-immunological-disease-and-adding" rel="noreferrer noopener">approximately&nbsp;$9.1 billion</a>.
Blueprint shareholders will also receive one contingent value right (CVR), which entitles the holder to two potential milestone payments of&nbsp;$2&nbsp;and&nbsp;$4&nbsp;per CVR to achieve future development and regulatory milestones for BLU-808.
The total equity value of the transaction, including potential CVR payments, represents approximately&nbsp;$9.5 billion&nbsp;on a fully diluted basis.
Paul Hudson, CEO of Sanofi, said, &#8220;The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios&#8230;It complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions.&#8221;&nbsp;
Ayvakit achieved net revenues of&nbsp;$479 million&nbsp;in 2024 and nearly&nbsp;$150 million&nbsp;in Q1 2025, representing year-on-year growth of more than 60% over Q1 2024.
Sanofi currently expects to complete the acquisition in the third quarter of 2025. The acquisition will not significantly impact Sanofi&#8217;s financial guidance for 2025. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026.
In another development, Sanofi exercised its option to exclusively license Nurix Therapeutics, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) STAT6 program on Monday, including the drug development candidate NX-3911, an oral, highly selective STAT6 degrader.
STAT6 (signal transducer and activator of transcription 6) plays a central role in type 2 inflammation, which drives diseases such as atopic dermatitis and asthma.
Under its 2019 collaboration agreement, Nurix will receive a $15 million license extension fee from Sanofi, bringing the total amount received under this <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45717764/sanofi-exercises-license-extension-option-to-nurixs-stat6-program" rel="noreferrer noopener">collaboration to $127 million</a>.
Nurix is eligible for an additional $465 million in development, regulatory, and commercial milestones associated with the STAT6 program and potential future royalties and retains an option to co-develop and co-promote in the U.S.
Price Action: SNY stock is trading lower by 0.73% to $49.01, BPMC stock is trading higher by 26.8% to $128.50, and NRIX stock is trading lower by 0.28% to $10.60 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45703311/us-listed-chinese-stocks-drop-after-trump-renews-trade-tensions" target="_blank" rel="noreferrer noopener">US Listed Chinese Stocks Drop After Trump Renews Trade Tensions</a></li>
</ul>
Photo by HJBC via Shutterstock

Health Care

Movers

BPMC

NRIX

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Buy now, pay later provider Klarna took another step toward a U.S. listing last week, <a href="https://www.klarna.com/international/press/klarna-accelerates-global-momentum-in-q1-2025-and-unlocks-large-gains-from/">reporting progress</a> on its transition into internally developed AI systems. AI-driven staff reductions of 700 contractors have generated "significant efficiency" according to the Swedish company, which now expects revenue per employee to reach $1 million, higher than the $575,000 reported last year.
Buy now, pay later payment processing services let retailers offer short-term installment loans at the time of purchase, allowing buyers to spread out payments. The loans are usually interest-free and without service charges, potentially encouraging customers to buy more than they can afford. Not surprisingly, these firms have come under investigation. Notably, the Swedish Financial Supervisory Authority hit Klarna with <a href="https://www.fintechfutures.com/bnpl-payments/swedish-regulator-issues-klarna-with-administrative-fine-of-around-46m#:~:text=The%20regulator%20says%20it%20investigated,violation%20of%20several%20key%20rules%E2%80%9D.">$46 million in fines</a> in December after accusing it of money laundering in 2021 and 2022.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
The company filed with the U.S. Securities and Exchange Commission for an <a href="https://www.sec.gov/Archives/edgar/data/2003292/000162828025012824/klarnagroupplcf-1.htm">IPO </a>in March, citing an American domicile in Columbus Ohio. It postponed plans after President Donald Trump announced tariffs on Europe in April and hasn't responded to the latest rejection by U.S. Federal courts. Klarna reported a 13% revenue increase to $710 million in the first quarter of 2025 but still hasn't said when it will proceed with the offering.&nbsp;
The BNPL business model works by charging fees to merchants, like card processors. There may also be flat transaction fees and late fees for missed payments. The second issue could upend the industry after a recent <a href="https://www.bankrate.com/loans/personal-loans/buy-now-pay-later-survey/">Bankrate survey</a> reported that about "half of buy now, pay later users have experienced issues like overspending and missing payments." While these companies depend on late fees, high incidence rates may attract the attention of regulators.&nbsp;
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
Almost one-third of Americans have used BNPL, according to the survey. Klarna captured 9% of the report&#8217;s market share while <a href="https://www.benzinga.com/quote/PYPL">PayPal</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NYSE">PYPL</a>) led the pack with 15%. Half of customers reported "issues related to service." Of those, 24% mentioned "overspending," 16% "missed payments" and 15% "regretting a purchase." Gen Z users reported the highest rate of these issues, across all generations. It also revealed "consistent use across all income levels," which is surprising, given the greater financial struggles of the lower classes.
The survey highlights a consumer base increasingly burdened by inflation and stubbornly high credit card rates. Bankrate Senior Industry Analyst Ted Rossman summed up the findings, noting that "BNPL can be a good deal if you use it responsibly. It provides access to credit and can help users smooth out their cash flow. But sometimes it can lead to overspending, and you would have been better off waiting until you could pay for the item up front."
See Also: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
It's hard to predict Klarna's success as a publicly traded company, given the moral hazards of this business model and financial challenges imposed by a potential trade war. However, things look brighter on the regulatory front because the Trump administration is pulling back on oversight, similar to its first term, scheduling budget reductions in consumer and banking regulations.&nbsp;
For now, it's best to just follow the money. Q1 2025 marked Klarna's fourth consecutive profitable quarter. It also reported an impressive 100 million active consumers while merchant growth surged 27%. Those are impressive numbers for this rapidly growing financial services startup.
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>&nbsp;
Image: Shutterstock

Personal Finance

PYPL

Klarna's Downside: Buy Now, Pay Later Users Overspend And Miss Payments

Aqua Metals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>), a leader in sustainable lithium battery recycling, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/584,975. The newly allowed patent covers critical aspects of Aqua Metals' proprietary lithium battery recycling technology and further strengthens the Company's AquaRefining&#x2122; intellectual property portfolio.
Originally filed in January 2022, the application reflects years of R&amp;D that progressed from lab and bench-scale validation to successful pilot operations. Aqua Metals has demonstrated the ability to efficiently recover battery-grade lithium carbonate, as well as high-purity nickel and cobalt materials, using its novel, electrified, and regenerative hydrometallurgical process.
This patent protects core innovations in Aqua Metals' AquaRefining&#x2122; technology—an environmentally superior alternative to traditional recycling. The process offers estimated cost savings of approximately $1,100 per metric ton of black mass input versus conventional hydrometallurgical methods. It also eliminates sodium sulfate waste, generates negligible CO₂ emissions, and provides a safer workplace environment.

AQMS

Aqua Metals Secures Key U.S. Patent For Breakthrough Lithium Battery Recycling Technology, Further Strengthens The Co's AquaRefining Intellectual Property Portfolio

Coya is on track and plans to submit the IND for COYA 302 (a proprietary combination of the low dose-rhIL-2 + CTLA4-Ig) by the end of June supporting the initiation of the Phase 2b study in patients with ALS
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.coyatherapeutics.com&amp;esheet=54263067&amp;newsitemid=20250602775188&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=dd0a5b2c88a4afdcc6c1ab9865fe6f62">Coya Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) ("Coya") today announced the issuance of a U.S. patent relevant to its investigational ready-to-use (RTU) liquid formulation of IL-2. In particular, the U.S. Patent and Trademark Office (USPTO) has granted patent number US 12,312,389 B2, which covers methods of producing highly stable liquid formulations of IL-2 (aldesleukin). Through an existing agreement, Coya has the exclusive in-vivo rights to this patent and other related intellectual property spanning multiple indications both as monotherapy and combination therapies.

COYA

Coya Therapeutics Announces Issuance Of U.S. Patent Relevant To Investigational RTU Liquid Formulation Of IL-2

Jefferies analyst Stephanie Moore upgrades Rollins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) from Hold to Buy and raises the price target from $55 to $65.

Upgrades

Jefferies Upgrades Rollins to Buy, Raises Price Target to $65

Goldman Sachs analyst David Roman initiated coverage on three companies, explaining that diabetes technology, including insulin pumps and continuous glucose monitors (CGMs), is expected to grow at a <a href="https://www.benzinga.com/topic/diabetes">strong double-digit pace</a>.
<h3 class="wp-block-heading">Insulet</h3>
Goldman Sachs initiated coverage on Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), citing the company to benefit from accelerating the adoption of patch pump technology as it is the only participant in the category currently.
Goldman Sachs initiated Insulet on Thursday with a Buy rating and <a href="https://www.benzinga.com/quote/PODD/analyst-ratings" target="_blank" rel="noreferrer noopener">a price target of $380</a>. The analyst highlights the company&#8217;s pipeline, which can potentially strengthen its relative position. Sustained top-line growth should support outsized adjusted EBITDA results and yield meaningful upside over the next several years.
Analyst David Roman writes, &#8220;We expect Omnipod's superior form factor and relative differentiation as a result to be the key contributor to Insulet's share capture as the insulin pump market moves into its next leg of adoption. In our view, the company is best positioned for the opportunities ahead in insulin delivery growth.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44745766/fda-approves-dexcoms-15-day-wearable-glucose-management-system-us-launch-planned-in-second-half-of-2025" rel="noreferrer noopener">FDA Approves Dexcom&#8217;s 15-Day Wearable Glucose Management System. Company Plans US Launch</a>
<h3 class="wp-block-heading">Dexcom</h3>
Goldman Sachs initiated DexCom Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/DXCM/analyst-ratings" rel="noreferrer noopener">price target of $104</a>, supported by a constructive view of the company&#8217;s technology and long-term opportunity set.
Roman adds the potential upside from consumer-related adoption and strong P&amp;L leverage, which should continue through the balance of 2025.
&#8220;Taking all patient cohorts into consideration, we expect Dexcom to remain ahead in the established Type 1 and Type 2 MDI segments. And in the higher growth T2 Basal and non-insulin populations, we expect Dexcom will take some patient share from Abbott over the intermediate term, off a much lower relative base&#8230;&#8221;
The CGM market is still mainly a two-player race between Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) and DexCom, Roman says.
However, the pump market is becoming more crowded, with more companies entering and customer needs changing. Hence, Goldman Sachs reiterated Abbott as a Buy and Tandem Diabetes Care, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) as Neutral.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45321429/insulet-posts-strong-q1-results-raises-forecasts-on-momentum-in-us-and-abroad" rel="noreferrer noopener">Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad</a>
<h3 class="wp-block-heading">Beta Bionics</h3>
Goldman Sachs initiated coverage on newly listed Beta Bionics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>). The diabetes management solutions provider closed its upsized IPO of 13.8 million at $17&nbsp;per share in January, raising approximately <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43415288/beta-bionics-announces-closing-of-234-6-million-initial-public-offering-and-full-exercise-of-under" rel="noreferrer noopener">$212.1 million in gross proceeds</a>.
The analyst initiated a Neutral rating and a <a href="https://www.benzinga.com/quote/BBNX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $16</a>, noting the company's iLet technology is well-suited for a targeted segment of the Type 1 market.
<ul class="wp-block-list">
<li>iLet is still in the early adoption phase, so its short-term growth is expected to be stronger than that of other diabetes-related companies and similar-sized medical technology firms.</li>
<li>Also, market estimates mostly reflect the growth potential over the next few years. The stock's valuation also seems to factor in this expected growth and the likelihood that the company will need to raise more money to reach break-even cash flow.</li>
</ul>
Price Action: PODD stock is up 0.14% at $324.31, BBNX stock is up 10% at $16.90, and DXCM stock is up 1% at $85.71 at the last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/05/45693375/summit-therapeutics-closely-watched-lung-cancer-study-of-ivonescimab-misses-overall-survival-endpoint" target="_blank" rel="noreferrer noopener">Summit Therapeutics&#8217; Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint</a></li>
</ul>
Image: Shutterstock

Analyst Color

BBNX

DXCM

PODD

TNDM

Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges

General Mills And Lactalis Receive Regulatory Clearance For Sale OF U.S. Yogurt Transaction

LYRA

Lyra Therapeutics shares are trading higher after the company announced its ENLIGHTEN 2 Phase 3 trial of LYR-210 met its primary endpoint.

Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers
Data completes preclinical package for Investigational New Drug submission in mid-2025 with Phase 1 therapeutic study initiation expected in 4Q25
SYDNEY, Australia, June 02, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that preclinical data from studies with the Lu177-B7H3-monoclonal antibody RV01 demonstrated favourable biodistribution and showed that RV01 maintained high tumour uptake. In addition, the Fc region modifications of the monoclonal antibody (mAb) confirm a shorter half-life, compared to traditional mAbs. The shorter half-life and other Fc modifications have the potential to limit off-target exposure to the isotope and mitigate toxicities associated with traditional monoclonal antibody therapies.
RV01 is the Company's B7-H3-targeted radiopharmaceutical therapy designed with strong affinity for the 4Ig isoform of B7H3 that is highly expressed in tumours and not in healthy tissues, which is being developed in partnership with MD Anderson Cancer Center. The B7-H3 targeting monoclonal antibody (mAb) is designed to target various solid tumours that express the B7-H3 protein. High expression of this target is associated with a poor prognosis in many cancer types.
The new preclinical data corroborate conclusions from earlier preclinical mouse studies that identified a high-affinity antibody highly selective to the cancer-specific 4Ig isoform of the B7-H3 receptor, demonstrated complete regression of established solid tumours with treatment and showed promising evidence of immune system stimulation and the ability to confer immune memory.

RADX

Radiopharm Theranostics Says Preclinical Data From Studies With Lu177-B7H3-Monoclonal Antibody RV01 Demonstrates Favourable Biodistribution And Shows That RV01 Maintained High Tumour Uptake

Comments

KraneShares MSCI All China Health Care Index ETF

Interés en corto

KraneShares MSCI All China Health Care Index ETF (ARCA:KURE), Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL